GAL and metabolic dysfunction-associated steatotic liver disease: Recently, it was demonstrated that human patients with MASLD have increased levels of serum galanin and that daily 5-week-lasting treatment with CEL ameliorates HFD/high cholesterol-induced MASH in mice (He et al., 2023).